Search

Displaying results 1711 - 1720 of 7540 in total
  1. Drug

    CX-052075

    go.drugbank.com/drugs/DB31655
    Approved

    [L53408,L53423] The original approval was formulated with the JN.1 strain ([mRNA-1283]), but was ultimately updated to the sublineage LP.8.1.[L54586] … [L53408] It is the primary ingredient in mNEXSPIKE, a COVID-19 mRNA vaccine developed by Moderna.

  2. Drug

    Imlifidase

    go.drugbank.com/drugs/DB15258
    ApprovedInvestigational

    to non-self HLA antigens, face additional barriers to transplantation. … [A225836,A225921] Imlifidase is a cysteine protease and eliminates Fc-dependent effector functions such as CDC and ADCC by cleaving the heavy chains of human immunoglobulin G (IgG) antibodies.

  3. Drug

    Filgotinib

    go.drugbank.com/drugs/DB14845
    ApprovedInvestigational

    [A189165] Filgotinib is currently reserved for patients who cannot tolerate DMARDs, or who have been unable to achieve remission in response to one or more DMARDs.[L16616] … [A189165] Non-selective JAK inhibitors like [tofacitinib] target JAK1 and JAK3 subtypes with minimal activity at JAK2. In contrast, the newly approved filgotinib is a highly selective JAK1 inhibitor.

  4. Drug

    Mecasermin

    go.drugbank.com/drugs/DB01277
    ApprovedInvestigational

    The rhIGF-1 protein is synthesized in bacteria (E. coli) that have been modified by the addition of the gene for human IGF-1. … The amino acid sequence of the product is identical to that of endogenous human IGF-1.

  5. Drug

    Pentobarbital

    go.drugbank.com/drugs/DB00312
    ApprovedVet approved

    A short-acting barbiturate that is effective as a sedative and hypnotic (but not as an anti-anxiety) agent and is usually given orally. … It is prescribed more frequently for sleep induction than for sedation but, like similar agents, may lose its effectiveness by the second week of continued administration.

  6. Drug

    Vancomycin

    go.drugbank.com/drugs/DB00512
    ApprovedInvestigational

    29 2018, CutisPharma's Firvanq is the only FDA approved vancomycin oral liquid treatment option available for the the treatment of _Clostridium difficile_ associated diarrhea and enterocolitis caused by … It is a glycopeptide related to ristocetin that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear.

  7. Drug

    Potassium chloride

    go.drugbank.com/drugs/DB00761
    ApprovedInvestigationalWithdrawn

    products containing potassium chloride that supply 100 mg or more of potassium per dosage unit, except for controlled-release dosage forms and those products formulated for preparation of solution prior to

    Mixtures: Dextrose and Electrolyte No. 75, Super Daily No 2
  8. Drug

    Tiratricol

    go.drugbank.com/drugs/DB03604
    ApprovedInvestigational

    by chronic tissue thyrotoxicosis and abnormal neuronal development due to the impaired thyroid hormone uptake in the brain. … [L53383] It was first approved by the EMA on February 12, 2025 for the treatment of peripheral thyrotoxicosis in patients with monocarboxylate transporter 8 (MCT8) deficiency,[A274038] a disorder characterized

    Categories: Agents used to treat hypothyroidism
  9. Drug

    Cupric Chloride

    go.drugbank.com/drugs/DB09131
    Approved

    Cupric chloride, for injection, is a sterile, nonpyrogenic solution intended for use as an additive to solutions for Total Parenteral Nutrition (TPN).

    Mixtures: ADDAMEL N, ADDAMEL N
  10. Drug

    Elosulfase alfa

    go.drugbank.com/drugs/DB09051
    ApprovedInvestigational

    Elosulfase alfa is a synthetic version of the enzyme N-acetylgalactosamine-6-sulfatase. It was approved by the FDA in 2014 for the treatment of Morquio syndrome. … Elosulfase alfa was developed by BioMarin Pharmaceutical Inc. and is marketed under the brand Vimizim™.

    Synonyms: Recombinant human N-acetylgalactosamine-6-sulfatase, Recombinant human N-acetylgalactosamine-6-sulfatase (rhGALNS)